This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEC0D0AP_M.jpg
The net proceeds from the initial public offering will be used to advance the clinical development of the Company’s CTM-N2D product candidate; to continue technology development of the Company’s iPSC-gdNKT product candidate; to advance clinical development of the Company’s CTM-GDT product candidate; and the remainder to fund R&D activities and manufacturing expansion, and for working capital and general corporate purposes.
The Benchmark Company, LLC is acting as the Bookrunning manager and Axiom Capital Management, Inc. is acting as a co-managing underwriter, in connection with the offering.
The Securities and Exchange Commission (the “SEC“) declared effective a registration statement on Form F-1 relating to the shares on March 31, 2023. A final prospectus related to the offering will be filed and made available on the SEC’s website at https://www.sec.gov. The offering is being made only by means of a prospectus. Electronic copies of the final prospectus may be obtained, when available, from The Benchmark Company, LLC,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
